Comprehensive Genomic Profiling at the Cusp of Modern Precision Oncology: Interview with Dr. Nicolas Martin
Genetic testing has forayed into various therapeutic areas and it is starting to influence the field of oncology in a big way. “Roche’s acquisition of Foundation Medicine and its vision for personalized medicine shares its origin in the realization that in the last hundred years anatomical and histological classification of tumors is going through paradigm shift toward a pan tumor molecular classification. It is now clear that cancer originates from an accumulation of genetic alterations over a period of time and it is important to identify targetable driver mutations” says Dr. Nicolas Martin, International Scientific Lead at Roche Foundation Medicine. He firmly believes that comprehensive genomic profiling is the future and it definitely outperforms existing technologies.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02